Dermatology review says all GLP-1 use for skin conditions remains off-label

The wire

1. 01Bridges and colleagues write that no GLP-1 receptor agonist holds an FDA-approved dermatologic indication, so prescribing for psoriasis, hidradenitis suppurativa and wound healing is off-label.
2. 02The chapter maps legal and professional standards for off-label prescribing, obesity medicine certification as a competency pathway, the compounding controversy, and reimbursement barriers dermatologists face.
3. 03It is a narrative review rather than new data, and the authors note the evidence base for cutaneous indications is still evolving alongside the next-generation incretin pipeline.

From the source

GLP-1 Receptor Agonists in Dermatology: Prescribing Frameworks, Access, and the Emerging Pipeline

Clinics in dermatology · 2026 Sep 23 · Bridges AG et al.